JP2024505638A - 腫瘍特異的ネオアンチゲンのｍｈｃクラスｉまたはクラスｉｉ免疫原性を予測するためのディープラーニングモデル - Google Patents

腫瘍特異的ネオアンチゲンのｍｈｃクラスｉまたはクラスｉｉ免疫原性を予測するためのディープラーニングモデル Download PDF

Info

Publication number
JP2024505638A
JP2024505638A JP2023543396A JP2023543396A JP2024505638A JP 2024505638 A JP2024505638 A JP 2024505638A JP 2023543396 A JP2023543396 A JP 2023543396A JP 2023543396 A JP2023543396 A JP 2023543396A JP 2024505638 A JP2024505638 A JP 2024505638A
Authority
JP
Japan
Prior art keywords
tumor
peptide
mhc class
specific
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505638A5 (https=
Inventor
サデー ギル
ヘッカーマン デイヴィッド
クリストファー プライス レイン
ウィルヘルム シュミッツ フランク
イマタ サフォ アンタ
カウル グルーウォル ジャスリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazon Technologies Inc
Original Assignee
Amazon Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazon Technologies Inc filed Critical Amazon Technologies Inc
Publication of JP2024505638A publication Critical patent/JP2024505638A/ja
Publication of JP2024505638A5 publication Critical patent/JP2024505638A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/044—Recurrent networks, e.g. Hopfield networks
    • G06N3/0442—Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/045—Combinations of networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/0499—Feedforward networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/082—Learning methods modifying the architecture, e.g. adding, deleting or silencing nodes or connections
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/0895—Weakly supervised learning, e.g. semi-supervised or self-supervised learning
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/09—Supervised learning
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/096—Transfer learning
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs

Landscapes

  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Computational Linguistics (AREA)
  • Computing Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioethics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023543396A 2021-01-19 2021-12-01 腫瘍特異的ネオアンチゲンのｍｈｃクラスｉまたはクラスｉｉ免疫原性を予測するためのディープラーニングモデル Pending JP2024505638A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163139074P 2021-01-19 2021-01-19
US63/139,074 2021-01-19
PCT/US2021/061399 WO2022159176A1 (en) 2021-01-19 2021-12-01 A deep learning model for predicting tumor-specific neoantigen mhc class i or class ii immunogenicity

Publications (2)

Publication Number Publication Date
JP2024505638A true JP2024505638A (ja) 2024-02-07
JP2024505638A5 JP2024505638A5 (https=) 2024-12-10

Family

ID=80122521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543396A Pending JP2024505638A (ja) 2021-01-19 2021-12-01 腫瘍特異的ネオアンチゲンのｍｈｃクラスｉまたはクラスｉｉ免疫原性を予測するためのディープラーニングモデル

Country Status (5)

Country Link
US (1) US12567480B2 (https=)
EP (1) EP4281970A1 (https=)
JP (1) JP2024505638A (https=)
CN (1) CN117136410A (https=)
WO (1) WO2022159176A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116959581A (zh) * 2023-01-17 2023-10-27 腾讯科技（深圳）有限公司 免疫原性预测模型的训练方法、装置、设备及存储介质
KR20250058439A (ko) * 2023-10-23 2025-04-30 주식회사 Lg 경영개발원 비관측 단백질 복합체를 활용하여 항원 제시 모델을 생성하는 단백질 상호 작용 예측 장치 및 이를 이용한 방법
WO2025128926A1 (en) 2023-12-13 2025-06-19 Amazon Technologies, Inc. Methods of identifying and treating individuals with elevated cancer risk
US20250197924A1 (en) 2023-12-15 2025-06-19 Amazon Technologies, Inc. Methods for selection and combination of sequencing results from biological samples for neoantigen scoring
CN117877603B (zh) * 2024-01-11 2024-09-13 天津大学 一种基于分层信息提取机制的化学反应理论产量预测方法
WO2026072916A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Structural variant detection in circulating tumor dna
WO2026073127A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Dual assay to boost accuracy of detected actionable variants in liquid biopsy
CN119152945A (zh) * 2024-10-08 2024-12-17 中国人民解放军海军军医大学第一附属医院 一种NeoBert模型及其在鉴别肿瘤新抗原中的应用
CN120048333B (zh) * 2025-02-14 2025-10-21 三二〇一医院 一种新抗原的筛选方法、设备及程序产品
CN119964812A (zh) * 2025-04-10 2025-05-09 成都大学附属医院(成都市创伤骨科研究所) 基于深度学习的前列腺癌医学智能预测系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106638A1 (en) * 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
CN111415707A (zh) * 2020-03-10 2020-07-14 四川大学 临床个体化肿瘤新抗原的预测方法
US20200276288A1 (en) * 2019-03-01 2020-09-03 Flow Pharma, Inc. Method of making a personalized cancer vaccine
WO2020234188A1 (en) * 2019-05-17 2020-11-26 Nec Oncoimmunity As Method and system for binding affinity prediction and method of generating a candidate protein-binding peptide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
EP3759131A4 (en) * 2018-02-27 2021-12-01 Gritstone bio, Inc. NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS
CN112071361B (zh) * 2020-04-11 2024-05-24 信华生物药业(广州)有限公司 基于Bi-LSTM与Self-Attention的多肽TCR免疫原性预测方法
CN112002374B (zh) * 2020-06-14 2022-04-22 北京臻知医学科技有限责任公司 基于深度学习的mhc-i表位亲和力预测方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106638A1 (en) * 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US20200276288A1 (en) * 2019-03-01 2020-09-03 Flow Pharma, Inc. Method of making a personalized cancer vaccine
WO2020234188A1 (en) * 2019-05-17 2020-11-26 Nec Oncoimmunity As Method and system for binding affinity prediction and method of generating a candidate protein-binding peptide
CN111415707A (zh) * 2020-03-10 2020-07-14 四川大学 临床个体化肿瘤新抗原的预测方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIMOTHY J. O’DONNELL ET AL.: "MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Ant", CELL PRESS，［ONLINE］, vol. Volume 11, Issue 1, JPN6025050080, 22 July 2020 (2020-07-22), pages 1 - 20, ISSN: 0005749261 *

Also Published As

Publication number Publication date
EP4281970A1 (en) 2023-11-29
CN117136410A (zh) 2023-11-28
WO2022159176A1 (en) 2022-07-28
US20230074591A1 (en) 2023-03-09
US12567480B2 (en) 2026-03-03

Similar Documents

Publication Publication Date Title
US12567480B2 (en) Deep learning model for predicting tumor-specific neoantigen MHC class I or class II immunogenicity
Yang et al. DNA vaccine for cancer immunotherapy
US20230173045A1 (en) Ranking neoantigens for personalized cancer vaccine
JP7175951B2 (ja) 免疫原性変異体ペプチドスクリーニングプラットフォーム
JP2025175055A (ja) 新生抗原のためのジャンクションエピトープ提示の低減
ES3029080T3 (en) Neoantigen identification using hotspots
Tarang et al. In silico design of a multivalent vaccine against Candida albicans
Snyder et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma
ES2970865T3 (es) Identificación, fabricación y uso de neoantígenos
KR20190140935A (ko) 신생항원 동정, 제조, 및 용도
US20170028043A1 (en) Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods Therefor
Atapour et al. In silico designing a candidate vaccine against breast cancer
Brennick et al. An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection
Polyakova et al. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens
Sufyan et al. Implementation of vaccinomics and in-silico approaches to construct multimeric based vaccine against ovarian cancer
US11887710B2 (en) Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine
Liu et al. A DNA vaccine targeting p42. 3 induces protective antitumor immunity via eliciting cytotoxic CD8+ T lymphocytes in a murine melanoma model
US11920202B2 (en) Unbiased identification of tumor rejection mediating neoepitopes
US20240360515A1 (en) Monitoring circulating tumor dna to improve subclone penetration of follow-up neoantigen cancer vaccines
Restifo Hierarchy, tolerance, and dominance in the antitumor T-cell response
Zahraei et al. In silico design of a multi-epitope vaccine against the triple negative breast cancer
Slathia et al. Conserved epitopes in variants of amastin protein of Trypanosoma cruzi for vaccine design: A bioinformatics approach
González-Cao et al. Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients
Tarabini et al. Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential
Uemura et al. Tumor vaccines in renal cell carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260407